Literature DB >> 4318783

Group-specific antigen expression during embryogenesis of the genome of the C-type RNA tumor virus: implications for ontogenesis and oncogenesis.

R J Huebner, G J Kelloff, P S Sarma, W T Lane, H C Turner, R V Gilden, S Oroszlan, H Meier, D D Myers, R L Peters.   

Abstract

Tests for the group-specific antigen of the C-type RNA tumor virus showed that mouse embryos of all strains tested, at some stage of development in utero, revealed detectable titers of group-specific antigen in one or more of their tissues; younger, rather than older, embryos were likely to be positive, particularly in those strains which normally reveal little or no expression of the RNA genome postnatally. The antigens were found in embryos of low-leukemia strains, free of infectious virus. These new findings support a previously stated hypothesis that the genome of RNA tumor viruses, mostly switched off for infectious virus expression, is vertically transmitted as part of the natural genetic apparatus of normal mouse cells. Since group-specific antigens have also been described in chick embryos and immunological tolerance to homologous group-specific antigens has been demonstrated in hamsters and cats as well as in mice and chickens, the hypothesis has been extended to include vertebrate cells in general. Finally, the high incidence and titers of the group-specific antigen suggest that the genes for RNA tumor virus, which later in life act as determinants of cancer, may be important also as gene determinants in the developing embryo.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4318783      PMCID: PMC283214          DOI: 10.1073/pnas.67.1.366

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo.

Authors:  G Schumann; M Hermankova; K Cannon; J L Mankowski; J D Boeke
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane.

Authors:  E A Pillemer; D A Kooistra; O N Witte; I L Weissman
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

3.  Viral-related RNA in Hodgkins' disease and other human lymphomas.

Authors:  R Hehlmann; D Kufe; S Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

4.  Reproductive fitness of P1, P2, and Mu lysogens of Escherichia coli.

Authors:  G Edlin; L Lin; R Bitner
Journal:  J Virol       Date:  1977-02       Impact factor: 5.103

5.  Expression of endogenous retroviral glycoprotein 70 by antigen-activated cytotoxic and suppressor T lymphocytes of nice.

Authors:  D Klenner; I Horak; A Schimpl; E Wecker
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

6.  Suppressive effect of immunization with mouse fetal antigens on growth of cells infected with Rauscher leukemia virus and plasma-cell tumors.

Authors:  M G Hanna; R W Tennant; J H Coggin
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

7.  Species and interspecies radioimmunoassays for rat type C virus p30: interviral comparisons and assay of human tumor extracts.

Authors:  H P Chapman; M H White; R Rahman; R V Gilden
Journal:  J Virol       Date:  1975-01       Impact factor: 5.103

8.  Neoplasms, differentiations and mutations.

Authors:  G B Pierce
Journal:  Am J Pathol       Date:  1974-10       Impact factor: 4.307

9.  C-type virus protein p30 in blood from inbred mice correlates with their later incidence of leukemia.

Authors:  B A Nexø; H H Krog
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

10.  Properties of density gradient-fractionated peripheral blood leukocytes from cattle infected with bovine leukemia virus.

Authors:  S J Kenyon; C E Piper
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.